Immunic Releases Promising Long-Term Data on Vidofludimus Calcium for MS

Immunic, Inc. has announced positive long-term open-label extension data from its Phase 2 EMPhASIS trial on vidofludimus calcium for relapsing-remitting multiple sclerosis (RRMS). At week 144, 92.3% of patients showed no 12-week confirmed disability worsening (CDW), and 92.7% were free of 24-week CDW. The data confirms low instances of relapse-associated worsening and progression independent of relapse activity.

Vidofludimus calcium has maintained a favorable safety and tolerability profile over nearly 5.5 years, with low discontinuation and adverse event rates. Immunic highlights the drug's potential in delaying disease progression, maintaining neurological function, and improving quality of life.

The phase 2 trial was designed to test the efficacy and safety of vidofludimus calcium and included multiple dosages. Significant results achieved in both primary and secondary endpoints underlined its potential as a novel oral therapy for MS.